definiens: ( as defined below ), in which - ' * case the Stop Shop Fee shall be equal to Fifteen Million Dollars ( $ 15,000, 000 ) ; or ( ii ) " \L Stressgen is at the time such Stop Shop Fee is paid by [COMPANY], conducting a Phase III ~ Clinical Trial for RRP as well as a Phase III Clinical Trial for an additiona l Non - GW ) .L Indication, where each such trial is a pivotal trial conducted using First Generation ~ Product material that has been manufactured pursuant to an Accepted Process, in ' * " 13 [ * * * ] Confidential Treatment Requested which case the Stop Shop Fee shall be equal to Twenty Million Dollars ( $ 20,OOO, oool ] + As used herein, an means a process that ( A ) Stressgen represents in writing to [COMPANY] is the final process for manufacture of the First Generation Product and intended to be the process it will use for commercial production of the First Generation Product, if approved ; and ( 8) has been reviewed and accepted by the FDA for the commencement of Phase III Clinical Trials of the First Generation Product . Any amounts paid by [COMPANY] pursuant to Sections 6.2 and 6.3 with respect to the Second Generation Development License G"hall be creditable against the Stop Shop ~ee, In 1 ' : addition, the Stop Shop Fee Differential ( as defined below ) shall be creditable against * the Option Exercise Fee, if paid . As used herein, the ¥ -